Also known as carcinoma in situ of the urinary bladder or high grade intraurothelial neoplasia, this is a flat lesion of the transitional cell epithelium characterized by severe cytologic atypia. This...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on bladder carcinoma in situ is limited due to its relatively rare occurrence and the complexity of its clinical features. The lack of systematic studies and genetic characterization contributes to this gap in knowledge. As a result, many patients may feel isolated in their experience, but ongoing research aims to improve understanding and treatment options.
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
There are currently 21 active clinical trials exploring various treatment options for bladder carcinoma in situ. Notably, the FDA has approved Valrubicin for this condition, and Imiquimod is designated for development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for 'bladder carcinoma in situ' at https://clinicaltrials.gov/search?cond=bladder%20carcinoma%20in%20situ. This research landscape offers hope for advancements in treatment and management of the condition.
Actionable guidance for navigating care for bladder carcinoma in situ
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on bladder carcinoma in situ is limited due to its relatively rare occurrence and the complexity of its clinical features. The lack of systematic studies and genetic characterization contributes to this gap in knowledge. As a result, many patients may feel isolated in their experience, but ongoing research aims to improve understanding and treatment options.
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
There are currently 21 active clinical trials exploring various treatment options for bladder carcinoma in situ. Notably, the FDA has approved Valrubicin for this condition, and Imiquimod is designated for development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for 'bladder carcinoma in situ' at https://clinicaltrials.gov/search?cond=bladder%20carcinoma%20in%20situ. This research landscape offers hope for advancements in treatment and management of the condition.
Actionable guidance for navigating care for bladder carcinoma in situ
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on bladder carcinoma in situ is limited due to its relatively rare occurrence and the complexity of its clinical features. The lack of systematic studies and genetic characterization contributes to this gap in knowledge. As a result, many patients may feel isolated in their experience, but ongoing research aims to improve understanding and treatment options.
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
There are currently 21 active clinical trials exploring various treatment options for bladder carcinoma in situ. Notably, the FDA has approved Valrubicin for this condition, and Imiquimod is designated for development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for 'bladder carcinoma in situ' at https://clinicaltrials.gov/search?cond=bladder%20carcinoma%20in%20situ. This research landscape offers hope for advancements in treatment and management of the condition.
Actionable guidance for navigating care for bladder carcinoma in situ
To navigate your care effectively, consider consulting a urologist with expertise in bladder cancer management, particularly one familiar with carcinoma in situ. Engaging with clinical trials can also be beneficial; inquire about eligibility for ongoing studies. For additional support, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While there are no specific patient organizations identified for bladder carcinoma in situ, reaching out to broader cancer support groups may also offer community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.